Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
2002 14
2003 12
2004 6
2005 10
2006 5
2007 8
2008 9
2009 5
2010 7
2011 5
2012 6
2013 2
2014 2
2015 2
2016 3
2017 7
2018 10
2019 5
2020 7
2021 12
2022 10
2023 28
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

160 results

Results by year

Filters applied: . Clear all
Page 1
Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study.
Menzies-Gow A, Wechsler ME, Brightling CE, Korn S, Corren J, Israel E, Chupp G, Bednarczyk A, Ponnarambil S, Caveney S, Almqvist G, Gołąbek M, Simonsson L, Lawson K, Bowen K, Colice G; DESTINATION study investigators. Menzies-Gow A, et al. Lancet Respir Med. 2023 May;11(5):425-438. doi: 10.1016/S2213-2600(22)00492-1. Epub 2023 Jan 23. Lancet Respir Med. 2023. PMID: 36702146 Clinical Trial.
Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma.
Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, Barker P, Sproule S, Ponnarambil S, Goldman M; ZONDA Trial Investigators. Nair P, et al. N Engl J Med. 2017 Jun 22;376(25):2448-2458. doi: 10.1056/NEJMoa1703501. Epub 2017 May 22. N Engl J Med. 2017. PMID: 28530840 Free article. Clinical Trial.
Effects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to allergen: A randomized controlled trial.
Corren J, Larson D, Altman MC, Segnitz RM, Avila PC, Greenberger PA, Baroody F, Moss MH, Nelson H, Burbank AJ, Hernandez ML, Peden D, Saini S, Tilles S, Hussain I, Whitehouse D, Qin T, Villarreal M, Sever M, Wheatley LM, Nepom GT, Sanda S; Immune Tolerance Network ITN057AD CATNIP Study Team. Corren J, et al. Among authors: moss mh. J Allergy Clin Immunol. 2023 Jan;151(1):192-201. doi: 10.1016/j.jaci.2022.08.029. Epub 2022 Oct 9. J Allergy Clin Immunol. 2023. PMID: 36223848 Clinical Trial.
Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial.
Harrison TW, Chanez P, Menzella F, Canonica GW, Louis R, Cosio BG, Lugogo NL, Mohan A, Burden A, McDermott L, Garcia Gil E, Zangrilli JG; ANDHI study investigators. Harrison TW, et al. Lancet Respir Med. 2021 Mar;9(3):260-274. doi: 10.1016/S2213-2600(20)30414-8. Epub 2020 Dec 22. Lancet Respir Med. 2021. PMID: 33357499 Clinical Trial.
Subtalar arthrodesis.
Moss M, Radack J, Rockett MS. Moss M, et al. Clin Podiatr Med Surg. 2004 Apr;21(2):179-201. doi: 10.1016/j.cpm.2004.01.001. Clin Podiatr Med Surg. 2004. PMID: 15063879 Review.
Quantitative CT Characteristics of Cluster Phenotypes in the Severe Asthma Research Program Cohorts.
Trivedi AP, Hall C, Goss CW, Lew D, Krings JG, McGregor MC, Samant M, Sieren JP, Li H, Schechtman KB, Schirm J, McEleney S, Peterson S, Moore WC, Bleecker ER, Meyers DA, Israel E, Washko GR, Levy BD, Leader JK, Wenzel SE, Fahy JV, Schiebler ML, Fain SB, Jarjour NN, Mauger DT, Reinhardt JM, Newell JD Jr, Hoffman EA, Castro M, Sheshadri A; NHLBI Severe Asthma Research Program (SARP). Trivedi AP, et al. Radiology. 2022 Aug;304(2):450-459. doi: 10.1148/radiol.210363. Epub 2022 Apr 26. Radiology. 2022. PMID: 35471111 Free PMC article.
160 results